Key Highlights
- ARK Invest acquired 85,485 shares of Palantir totaling approximately $11.15M across five ETFs
- The firm divested 44,446 AMD shares valued at roughly $10.52M, trimming semiconductor holdings
- Palantir experienced a ~2% decline Friday following Thursday’s 7% drop
- “Big Short” investor Michael Burry flagged Palantir as overvalued, pointing to Anthropic’s competitive threat
- Wedbush analyst Daniel Ives countered Burry’s stance, reaffirming his Buy rating with a $230 target
Cathie Wood’s investment firm ARK Invest executed significant portfolio adjustments during April 10-11, 2026. The company accumulated shares in Palantir Technologies while simultaneously reducing its position in Advanced Micro Devices, as revealed through daily trading disclosures.
The acquisition involved 85,485 Palantir shares with a combined value near $11.15 million. ARK distributed these holdings across its fund lineup: ARKK absorbed 46,455 shares, ARKQ received 15,127, ARKW added 11,865, ARKF took 5,973, and ARKX claimed 6,065.
Palantir Technologies Inc., PLTR
Concurrently, ARK divested its Advanced Micro Devices holdings, selling 44,446 shares for approximately $10.52 million. The sale was similarly distributed across ARK’s five primary funds.
This strategic reallocation indicates ARK’s preference for AI software infrastructure over traditional semiconductor manufacturers.
Market Headwinds for Palantir
Palantir’s stock faced significant turbulence in the days preceding ARK’s purchase. Shares declined approximately 2% on Friday, compounding Thursday’s steeper 7% retreat.
The downturn gained momentum following comments from Michael Burry, the investor famous for predicting the 2008 financial crisis. Burry publicly stated on X that Palantir’s current valuation reflects “bubble” characteristics.
His skepticism centered on competitive dynamics, specifically highlighting how Anthropic’s “Mythos” AI model and aggressive expansion threaten Palantir’s market position. Despite this negative sentiment, Cathie Wood capitalized on the price weakness to increase exposure.
ARK simultaneously offloaded 75,389 Strata Critical Medical shares worth $305,325, extending a multi-day pattern of reducing that particular holding.
Wall Street Remains Split
Burry’s bearish perspective hasn’t achieved universal acceptance. Wedbush’s Daniel Ives sharply rejected the criticism, characterizing it as a “fictional narrative.”
Ives maintained his bullish stance, preserving both his Buy recommendation and $230 price objective. His optimism stems from Palantir’s impressive 137% expansion in U.S. Commercial segment revenue, which he views as confirmation of enduring competitive strength.
Benchmark’s Yi Fu Lee offers a more measured outlook. Lee acknowledges that Palantir’s elevated valuation multiples create pressure for consistent operational excellence to support current price levels.
Overall analyst sentiment toward Palantir registers as a Moderate Buy. This consensus emerges from 14 Buy recommendations, 5 Hold ratings, and 2 Sell opinions.
The mean analyst price target stands at $194.61 following recent market fluctuations, implying roughly 52% appreciation potential from Friday’s close.
Advanced Micro Devices stock gained 3.55% on the trading day ARK executed its exit.
